相似文献
1
Pharmacotherapy for childhood obesity: present and future prospects.
Int J Obes (Lond). 2013 Jan;37(1):1-15. doi: 10.1038/ijo.2012.144. Epub 2012 Aug 28.
2
[The pharmacotherapy of obesity].
Acta Pharm Hung. 2015;85(1):3-17.
3
Pharmacological approaches for the treatment of obesity.
Drugs. 2002;62(6):915-44. doi: 10.2165/00003495-200262060-00005.
4
Drug strategies for the treatment of obesity.
IDrugs. 2003 Jun;6(6):566-72.
5
Current pharmacotherapy for obesity.
Nat Rev Endocrinol. 2018 Jan;14(1):12-24. doi: 10.1038/nrendo.2017.122. Epub 2017 Oct 13.
6
Pharmacotherapy of obesity: an update.
Nutr Clin Care. 2003 Jan-Apr;6(1):27-37.
7
Antiobesity effects of green tea catechins: a mechanistic review.
J Nutr Biochem. 2011 Jan;22(1):1-7. doi: 10.1016/j.jnutbio.2010.06.006. Epub 2010 Nov 5.
8
Pharmacotherapy for obesity.
Aust Fam Physician. 2017;46(7):472-477.
9
Pharmacotherapy of obesity: targets and perspectives.
Trends Pharmacol Sci. 2001 May;22(5):247-54. doi: 10.1016/s0165-6147(00)01664-3.
10
[Pharmacological therapy of obesity].
G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S.
引用本文的文献
1
Pediatric Obesity Treatment: Considerations for Diabetes Educators and Clinicians.
Diabetes Spectr. 2024 Nov 15;37(4):313-324. doi: 10.2337/dsi24-0005. eCollection 2024 Fall.
2
The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Adolescents Without Diabetes Mellitus: A Systematic Review and Meta-Analysis.
Cureus. 2024 Aug 6;16(8):e66280. doi: 10.7759/cureus.66280. eCollection 2024 Aug.
3
Causes, Consequences, and Preventive Strategies for Childhood Obesity: A Narrative Review.
Cureus. 2024 Jul 20;16(7):e64985. doi: 10.7759/cureus.64985. eCollection 2024 Jul.
4
Medication-induced weight gain and advanced therapies for the child with overweight and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement 2022.
Obes Pillars. 2022 Dec 5;4:100048. doi: 10.1016/j.obpill.2022.100048. eCollection 2022 Dec.
5
Recent advancements in pharmacological strategies to modulate energy balance for combating obesity.
RSC Med Chem. 2023 Jun 14;14(8):1429-1445. doi: 10.1039/d3md00107e. eCollection 2023 Aug 16.
6
Efficacy of Liraglutide in Obesity in Children and Adolescents: Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Children (Basel). 2023 Jan 25;10(2):208. doi: 10.3390/children10020208.
7
The anorexic effect of DL-fenfluramine is dependent on animals' habituation to different food types.
Front Integr Neurosci. 2022 Nov 16;16:1010181. doi: 10.3389/fnint.2022.1010181. eCollection 2022.
8
Signaling pathways in obesity: mechanisms and therapeutic interventions.
Signal Transduct Target Ther. 2022 Aug 28;7(1):298. doi: 10.1038/s41392-022-01149-x.
9
The promise of new anti-obesity therapies arising from knowledge of genetic obesity traits.
Nat Rev Endocrinol. 2022 Oct;18(10):623-637. doi: 10.1038/s41574-022-00716-0. Epub 2022 Jul 28.
10
Curcuminoids for Metabolic Syndrome: Meta-Analysis Evidences Toward Personalized Prevention and Treatment Management.
Front Nutr. 2022 Jun 9;9:891339. doi: 10.3389/fnut.2022.891339. eCollection 2022.
本文引用的文献
1
FDA approves Belviq to treat some overweight or obese adults.
Home Healthc Nurse. 2012 Sep;30(8):443-4.
2
Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c mRNA but not for feeding-dependent expression.
Cell Metab. 2012 Jun 6;15(6):873-84. doi: 10.1016/j.cmet.2012.05.002.
3
Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study.
Obesity (Silver Spring). 2012 Jul;20(7):1426-36. doi: 10.1038/oby.2012.66. Epub 2012 Mar 16.
4
Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010.
JAMA. 2012 Feb 1;307(5):483-90. doi: 10.1001/jama.2012.40. Epub 2012 Jan 17.
5
Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
J Clin Endocrinol Metab. 2012 Mar;97(3):1020-31. doi: 10.1210/jc.2011-2260. Epub 2012 Jan 11.
6
Association of biochemical B₁₂ deficiency with metformin therapy and vitamin B₁₂ supplements: the National Health and Nutrition Examination Survey, 1999-2006.
Diabetes Care. 2012 Feb;35(2):327-33. doi: 10.2337/dc11-1582. Epub 2011 Dec 16.
7
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
Am J Clin Nutr. 2012 Feb;95(2):297-308. doi: 10.3945/ajcn.111.024927. Epub 2011 Dec 7.
8
Childhood adiposity, adult adiposity, and cardiovascular risk factors.
N Engl J Med. 2011 Nov 17;365(20):1876-85. doi: 10.1056/NEJMoa1010112.
9
Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report.
Pediatrics. 2011 Dec;128 Suppl 5(Suppl 5):S213-56. doi: 10.1542/peds.2009-2107C. Epub 2011 Nov 14.
10
Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
Clin Ther. 2011 Dec;33(12):1932-42. doi: 10.1016/j.clinthera.2011.10.014. Epub 2011 Nov 10.
Zotero 插件